Maze Therapeutics, Inc.
MAZE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001842295
In the last 90 days, Maze Therapeutics, Inc. insiders filed 0 open-market purchases and 14 sales; 161 institutions reported holding it in 13F filings for Q2 2026, worth $1.75B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $6.19M in total
- 14
- 13F holdersQ2 2026, −1 vs. previous quarter
- 161
- 13F valueReported value at the end of Q2 2026
- $1.75B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding MAZE, Q2 2026
1 superinvestor reports holding Maze Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
HHLR Advisors (Hillhouse)
Zhang Lei
1.3%
Maze Therapeutics, Inc.'s share of the portfolio
- Shares
- 366,028
- Value
- $10.9M
Latest insider trades
Open-market purchases and sales by Maze Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 (view filing)4:20 PM ET | Sep 4 | 4 days | Bernstein HaroldPresident, R&D & CMO | SSale | −9.71K | $26.22 | −$254.5K | −100.0%0 after | 10b5-1 |
| Sep 4, 2026 (view filing)4:27 PM ET | Sep 2-3 | 2 days | Courtney PhillipsGC and Corp. Secretary | SSale | −3.99K | $26.24 | −$104.8K | −36.3%7.01K after | 4 lots |
| Sep 4, 2026 (view filing)4:25 PM ET | Sep 2-3 | 2 days | Dandekar AtulCSBO | SSale | −6.43K | $26.24 | −$168.8K | −16.6%32.3K after | 4 lots |
| Sep 4, 2026 (view filing)4:24 PM ET | Sep 2-3 | 2 days | Coloma Jason VChief Executive Officer | SSale | −22.6K | $26.24 | −$594.0K | −45.3%27.4K after | 4 lots |
| Sep 4, 2026 (view filing)4:22 PM ET | Sep 2-3 | 2 days | Bernstein HaroldPresident, R&D & CMO | SSale | −10.3K | $26.24 | −$270.1K | −51.5%9.71K after | 4 lots |
| Sep 3, 2026 (view filing)4:27 PM ET | Sep 1 | 2 days | Coloma Jason VChief Executive Officer | SSale | −34.5K | $26.29 | −$907.0K | −13.4%223.4K after | 2 lots10b5-1 |
| Sep 3, 2026 (view filing)4:24 PM ET | Sep 1 | 2 days | Bernstein HaroldPresident, R&D & CMO | SSale | −16.1K | $26.36 | −$425.5K | −100.0%0 after | 10b5-1 |
| Aug 31, 2026 (view filing)6:32 PM ET | Aug 28 | 3 days | Dandekar AtulCSBO | SSale | −7.50K | $27.58 | −$206.8K | −22.2%26.3K after | 10b5-1 |
| Aug 14, 2026 (view filing)4:54 PM ET | Aug 13 | 1 day | Bernstein HaroldPresident, R&D & CMO | SSale | −16.1K | $27.61 | −$445.6K | −100.0%0 after | 10b5-1 |
| Aug 5, 2026 (view filing)4:08 PM ET | Aug 3 | 2 days | Coloma Jason VChief Executive Officer | SSale | −34.5K | $26.73 | −$922.3K | −11.9%255.3K after | 4 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Maze Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 5,032,915 | $150.2M | 3.27% | +465,641+10.2% | Added |
| TRV GP IV, LLC | 4,473,958 | $133.5M | 52.63% | 00.0% | Unchanged |
| ARCH Venture Management, LLC | 4,120,053 | $123.0M | 11.18% | 00.0% | Unchanged |
| Deep Track Capital, LP | 3,732,569 | $111.4M | 1.64% | +255,007+7.3% | Added |
| BlackRock, Inc. | 3,502,841 | $104.5M | 0.00% | +932,416+36.3% | Added |
| Jupiter Topco LLC | 3,408,045 | $101.8M | 0.04% | +3,408,045 | New |
| T. Rowe Price Investment Management, Inc. | 2,603,682 | $77.7M | 0.05% | +2,603,682 | New |
| Logos Global Management LP | 1,935,000 | $57.7M | 2.49% | +700,000+56.7% | Added |
| Vanguard Capital Management LLC | 1,778,222 | $53.1M | 0.00% | +342,566+23.9% | Added |
| AH Capital Management, L.L.C. | 1,702,225 | $50.8M | 0.36% | 00.0% | Unchanged |